The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)
Clinical trial NCT00266799 · COMPLETED
Trial details
- NCT number
- NCT00266799
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2006-01-13
- Primary completion
- 2010-09-29
- Enrollment
- 210
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.